# Application of Deep Learning in Lung Cancer Imaging Diagnosis.

> **Reliability concern:** This paper was retracted on 2023-12-06. See notice: 10.1155/2023/9796232.

- **DOI:** [10.1155/2022/6107940](https://doi.org/10.1155/2022/6107940)
- **Rating:** Limited (2.7 out of 5)
- **Verdict:** A competent lung nodule CAD pipeline with competitive LUNA16 benchmark results, undermined by incomplete methodological reporting and absent clinical validation.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-01
- **Evaluation page:** https://www.nabu.science/paper/10.1155%2F2022%2F6107940

## Strengths

- **Competitive LUNA16 benchmark performance across two stages** The pipeline achieves FROC values of 0.876 for nodule detection and 0.883 for false positive reduction on the LUNA16 benchmark, placing it among competitive entries. The detection stage shows particularly high sensitivity, which is clinically valuable for screening applications where recall is prioritized.
  - Dimension: contribution
  - Location: Sections 4.1, 4.3; Figures 7-8
- **Systematic comparison of loss functions and network structures** The paper provides internal comparisons of different network structures (ResNet, DenseNet, U-Net variants) and loss functions (cross-entropy vs. weighted cross-entropy) for both false positive reduction and classification stages, with results reported in Tables 1-2. This provides evidence for design choices within the pipeline.
  - Dimension: methodological rigour
  - Location: Tables 1-2; Sections 3.3.2, 4.4
- **Coherent multi-stage pipeline addressing a documented clinical need** The three-stage design — detection, false positive filtering, and classification — mirrors the clinical diagnostic workflow and addresses the documented 30% nodule miss rate by radiologists. The Leaky Noise-or aggregation for multi-nodule classification adds a methodologically distinct element to the classification stage.
  - Dimension: application pathway
  - Location: Section 1 (Introduction); Section 4.4

## Limitations

- **Unconfirmed patient-level data splitting and unclear sample provenance** The nodule detection experiment describes 2000 original samples split 8:2, but does not confirm that splitting was performed at the patient level — a critical requirement in medical imaging to prevent data leakage. The relationship between these 2000 samples and the LUNA16 dataset (888 scans) is unexplained.
  - Dimension: methodological rigour
  - Location: Section 4.1
- **Material scope mismatch between Conclusion and paper content** The Conclusion states the paper examines 'CT images of lung cancer and thyroid cancer' and mentions 'benign and malignant classification of the thyroid,' but no thyroid-related methods, data, or results appear anywhere in the paper. This suggests incomplete assembly or revision of a broader work and undermines confidence in the paper's editorial integrity.
  - Dimension: reporting
  - Location: Section 5 (Conclusion)
- **Classification results lack external benchmarking** While detection and FPR stages are benchmarked against LUNA16 competition entries, the benign/malignant classification results (Tables 1-2) are compared only internally across the paper's own methods, with no comparison to published state-of-the-art classification approaches. This prevents assessment of whether the classification performance is competitive.
  - Dimension: contribution
  - Location: Section 4.4; Tables 1-2

## Reliability checks

Concerns (4 of 4 checks).

- **Internal coherence:** Noted. The paper contains a material scope mismatch: the Conclusion (Section 5) mentions thyroid cancer classification, but no methods, data, or results for thyroid cancer appear anywhere in the paper. Additional issues include a duplicate citation number ([5] used for both Murphy et al. and U-Net) and inconsistent figure cross-references.
- **Research conduct:** Noted. Data availability is claimed as 'upon reasonable request' with no named repository or persistent identifier, making verification impossible. No ethics approval statement is present, no conflict of interest disclosure is provided, and no code is released. The use of publicly available datasets (LUNA16, LIDC-IDRI) partially mitigates data provenance concerns, but the '2000 original samples' used for nodule detection are not clearly sourced.
- **Reference integrity:** Clean. All 16 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Concern
- **Summary:** This paper was retracted on 2023-12-06. See notice: 10.1155/2023/9796232.
- **Last checked:** 2026-10-17
